By combining clinical, morphological and biochemical markers a better understanding of the formation and progression of multiple sclerosis (MS) should be obtained
The current study aims to comprehensively investigate the individual clinical, morphological and biochemical aspects of MS in order to elucidate underlying mechanisms leading to disease progression. This shall ultimately serve to identify imaging and biochemical markers, which may support clinical management of persons with MS (pwMS). The following markers will be assessed: demographics (age, sex), clinical (EDSS at baseline, disease duration); neuropsychological (SDMT (Symbol Digit Modalities Test) score); MRI (Magnetic Resonance Imaging) (lesion load, atrophy); Biochemical markers analyzed in cerebrospinal fluid (CSF), blood, DNA, RNA, peripheral blood mononuclear cells (PBMCs)
Study Type
OBSERVATIONAL
Enrollment
500
40-50 ml of blood is taken
Medical University of Graz
Graz, Styria, Austria
RECRUITINGPrediction of EDSS ( Expanded Disability Status Scale) progression by combined markers of the disease
EDSS score
Time frame: a maximum of 4 years
Prediction of clinical relapses
Prediction of clinical relapses
Time frame: a maximum of 4 years
Conversion from CIS (Clinically Isolated Syndrome) to MS (Multiple Sclerosis) defined by MRI and clinical criteria
Conversion from CIS to MS defined by MRI and clinical criteria
Time frame: a maximum of 4 years
Time of transition to progressive form of MS
Time of transition to progressive form of MS
Time frame: a maximum of 4 years
Neuropsychological progression (decrease in SDMT performance)
Neuropsychological progression (decrease in SDMT performance)
Time frame: a maximum of 4 years
Increase in morphological damage (lesion load, atrophy)
Increase in morphological damage (lesion load, atrophy)
Time frame: a maximum of 4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.